Format

Send to

Choose Destination
See comment in PubMed Commons below
Antimicrob Agents Chemother. 2010 Jun;54(6):2670-3. doi: 10.1128/AAC.01703-09. Epub 2010 Mar 22.

Telbivudine exhibits no inhibitory activity against HIV-1 clinical isolates in vitro.

Author information

1
Novartis Institutes for Biomedical Research, Inc., Cambridge, MA 02139, USA. kai.lin@novartis.com

Abstract

Most approved drugs with activity against hepatitis B virus (HBV) have activity against human immunodeficiency virus type 1 (HIV-1), which precludes their use in patients who are coinfected with HBV and HIV-1 and who are not receiving antiretroviral therapy due to the risk of inducing resistance. The activity of telbivudine, a highly selective HBV inhibitor, against temporally and geographically distinct wild-type and multidrug-resistant HIV-1 clinical isolates was evaluated in vitro. No inhibition was observed with up to 600 muM drug, which supports further exploration of telbivudine as a therapeutic option for the treatment of HBV infections in patients coinfected with HIV-1.

PMID:
20308377
PMCID:
PMC2876362
DOI:
10.1128/AAC.01703-09
[Indexed for MEDLINE]
Free PMC Article
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for PubMed Central
    Loading ...
    Support Center